Arnica Betula A
- Manufacturer
- Uriel Pharmacy Inc.
- Effective date
- 2024-12-12
- Label type
- HUMAN OTC DRUG LABEL
- Version
- 4
- Source
- full-release
- Hydrated at
- 2026-06-01 02:29:36
Label at a glance#
Contacts and useful links#
Label contents#
Full prescribing information#
INDICATIONS & USAGE SECTION
Directions: FOR ORAL USE ONLY.
DOSAGE & ADMINISTRATION SECTION
Dissolve pellets under the tongue 3-4 times daily. Ages 12 and older: 10 pellets. Ages 2-11: 5 pellets. Under age 2: Consult a doctor.
OTC - ACTIVE INGREDIENT SECTION
Active Ingredients: Betula (Silver birch leaves) 3X, Betula (Silver birch bark) 4X, Cerebellum (Bovine cerebellum) 17X, Corpora quadrig. (Bovine Quadrigeminal plate) 17X, Hypophysis (Bovine pituitary gland) 17X, Iris -bovis (Bovine iris) 17X, Medulla oblong. (Bovine Myelencephalon) 17X, Nervus opticus (Bovine second cranial nerve) 17X, Retina et chor. (Bovine retina and choroid) 17X, Thalamus (Bovine thalamus) 17X, Arnica 30X, Chrysolith (Silicate of magnesium and iron) 30X, Formica (Red wood ant) 30X, Plumbum mellitum (Lead with honey) 30X
INACTIVE INGREDIENT SECTION
Inactive Ingredient: Organic sucrose
Prepared using rhythmical processes.
OTC - PURPOSE SECTION
Use: Temporary relief of headache.
OTC - KEEP OUT OF REACH OF CHILDREN SECTION
KEEP OUT OF REACH OF CHILDREN.
WARNINGS SECTION
Warnings: Claims based on traditional homeopathic practice, not accepted medical evidence. Not FDA evaluated. Contains sugar. Diabetics and persons intolerant of sucrose (sugar): Consult a doctor before use. Do not use if allergic to any ingredient. Consult a doctor before use for serious conditions or if conditions worsen or persist. If pregnant or nursing, consult a doctor before use. Do not use if safety seal is broken or missing.
OTC - QUESTIONS SECTION
Questions? Call 866.642.2858 Uriel, East Troy, WI 53120 shopuriel.com Lot:
PACKAGE LABEL.PRINCIPAL DISPLAY PANEL
FDA-Initiated Inactive NDC Indexing#
| NDC | Effective | Action | Document | Indexing SPL | Related label |
|---|---|---|---|---|---|
| 48951-1115-2 | 2026-01-29 | C162847 | 48780-1 | 49896155-ac70-586f-e063-e6dba90add90 | Arnica Betula A |
DailyMed Package Descriptions#
| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|---|---|---|---|---|---|
| 48951-1115-2 | Arnica Betula A | 1350 in 1 BOTTLE, GLASS | PELLET | 1350 | 4 |
DailyMed Dashboard NDC Coverage#
| NDC | Dashboard title | SPL version | Validation | Dashboard ZIP |
|---|---|---|---|---|
| 48951-1115 | ARNICA BETULA A PELLET [URIEL PHARMACY INC.] | 4 | Legacy NDC, 1 package rows | 20241215_6ccfc019-f903-48ad-b05e-f560e4a21df9.zip |
DailyMed Socrata Ingredients#
| Ingredient | Type | UNII | SPL version | Uploaded |
|---|---|---|---|---|
| ARNICA MONTANA | ACTIVE INGREDIENT | O80TY208ZW | 1 | |
| BETULA PUBESCENS BARK | ACTIVE INGREDIENT | 3R504894L9 | 1 | |
| BETULA PUBESCENS LEAF | ACTIVE INGREDIENT | 84SOH0O3OO | 1 | |
| BOS TAURUS BRAIN | ACTIVE INGREDIENT | A1YEE2DB8Z | 1 | |
| BOS TAURUS CEREBELLUM | ACTIVE INGREDIENT | Q09851U44F | 1 | |
| BOS TAURUS EYE | ACTIVE INGREDIENT | VTW461N43P | 1 | |
| BOS TAURUS NERVE | ACTIVE INGREDIENT | 28G2U3MQJK | 1 | |
| BOS TAURUS PITUITARY GLAND | ACTIVE INGREDIENT | 7JM57I419K | 1 | |
| COLLOIDAL SILICON DIOXIDE | ACTIVE INGREDIENT | ETJ7Z6XBU4 | 1 | |
| LEAD | ACTIVE INGREDIENT | 2P299V784P | 1 | |
| SUS SCROFA THALAMUS | ACTIVE INGREDIENT | 3D6Q7UV74J | 1 | |
| ARNICA MONTANA | ACTIVE MOIETY | O80TY208ZW | 1 | |
| BETULA PUBESCENS BARK | ACTIVE MOIETY | 3R504894L9 | 1 | |
| BETULA PUBESCENS LEAF | ACTIVE MOIETY | 84SOH0O3OO | 1 | |
| BOS TAURUS BRAIN | ACTIVE MOIETY | A1YEE2DB8Z | 1 | |
| BOS TAURUS CEREBELLUM | ACTIVE MOIETY | Q09851U44F | 1 | |
| BOS TAURUS EYE | ACTIVE MOIETY | VTW461N43P | 1 | |
| BOS TAURUS NERVE | ACTIVE MOIETY | 28G2U3MQJK | 1 | |
| BOS TAURUS PITUITARY GLAND | ACTIVE MOIETY | 7JM57I419K | 1 | |
| COLLOIDAL SILICON DIOXIDE | ACTIVE MOIETY | ETJ7Z6XBU4 | 1 | |
| LEAD | ACTIVE MOIETY | 2P299V784P | 1 | |
| SUS SCROFA THALAMUS | ACTIVE MOIETY | 3D6Q7UV74J | 1 | |
| SUCROSE | INACTIVE INGREDIENT | C151H8M554 | 1 |
Products#
Every source-derived product name is available through these pages.
- Arnica Betula A
- SUCROSE
- BETULA PUBESCENS LEAF
- BETULA PUBESCENS BARK
- BOS TAURUS CEREBELLUM
- BOS TAURUS BRAIN
- BOS TAURUS PITUITARY GLAND
- BOS TAURUS EYE
- BOS TAURUS NERVE
- SUS SCROFA THALAMUS
- ARNICA MONTANA
- SILICON DIOXIDE
- LEAD
NDC Codes#
| Product NDC | Package NDC |
|---|---|
| 48951-1115 | 48951-1115-2 |
Ingredients#
Every source-derived ingredient row is available through these pages.
| Name | UNII | Kind |
|---|---|---|
| SUCROSE | C151H8M554 | IACT |
| BETULA PUBESCENS LEAF | 84SOH0O3OO | ACTIB |
| BETULA PUBESCENS BARK | 3R504894L9 | ACTIB |
| BOS TAURUS CEREBELLUM | Q09851U44F | ACTIB |
| BOS TAURUS BRAIN | A1YEE2DB8Z | ACTIB |
| BOS TAURUS PITUITARY GLAND | 7JM57I419K | ACTIB |
| BOS TAURUS EYE | VTW461N43P | ACTIB |
| BOS TAURUS NERVE | 28G2U3MQJK | ACTIB |
| SUS SCROFA THALAMUS | 3D6Q7UV74J | ACTIB |
| ARNICA MONTANA | O80TY208ZW | ACTIB |
| SILICON DIOXIDE | ETJ7Z6XBU4 | ACTIB |
| LEAD | 2P299V784P | ACTIB |
Source Document#
Inactive ingredient matches#
Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.
| DailyMed ingredient | IID ingredient | UNII | Dosage form / route | Potency | Maximum daily exposure | Match |
|---|---|---|---|---|---|---|
| SUCROSE | SUCROSE | C151H8M554 | CAPSULE, EXTENDED RELEASE / ORAL | 619 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | TABLET, EXTENDED RELEASE / ORAL | 284.54 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | TABLET, DELAYED RELEASE / ORAL | 295.33 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | INJECTION / SUBCUTANEOUS | 47.75 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | INJECTION, SOLUTION / INTRAVENOUS | NA | ||
| SUCROSE | SUCROSE | C151H8M554 | INJECTION, SUSPENSION, LIPOSOMAL / INTRAVENOUS | 9.4 %w/v | ||
| SUCROSE | SUCROSE | C151H8M554 | WAFER / ORAL | 155.2 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION / SUBCUTANEOUS | 308 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | TABLET / BUCCAL | 109 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | LOZENGE / BUCCAL | NA | ||
| SUCROSE | SUCROSE | C151H8M554 | GRANULE, FOR SOLUTION / ORAL | 42596 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | SOLUTION / ORAL | 70000 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | LIQUID / ORAL | 37500 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | SYRUP / ORAL | 46400 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | CAPSULE / ORAL | 3568 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | SOLUTION / RECTAL | 35.42 %w/v | ||
| SUCROSE | SUCROSE | C151H8M554 | CAPSULE, COATED PELLETS / ORAL | 59.8 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | POWDER / ORAL | 27768 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | PASTILLE / ORAL | 426 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | LOZENGE / TRANSMUCOSAL | 1255 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | INJECTION / INTRAVENOUS | 1950 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | CAPSULE, COATED, EXTENDED RELEASE / ORAL | 86 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | SUSPENSION/ DROPS / ORAL | 3750 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | CAPSULE, DELAYED RELEASE / ORAL | 955 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | TROCHE / ORAL | NA | ||
| SUCROSE | SUCROSE | C151H8M554 | SUSPENSION, EXTENDED RELEASE / ORAL | 5400 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | TABLET, COATED / ORAL | 516.42 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | TABLET / SUBLINGUAL | 109 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | GRANULE, FOR SUSPENSION / ORAL | 31885 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | TROCHE / BUCCAL | NA | ||
| SUCROSE | SUCROSE | C151H8M554 | TABLET, CHEWABLE / ORAL | 7258 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | INJECTION, EMULSION / INTRAVENOUS | 970 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | TABLET, FILM COATED / ORAL | 145 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | SUSPENSION / ORAL | 48209 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | GRANULE / ORAL | NA | ||
| SUCROSE | SUCROSE | C151H8M554 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION / INTRAVENOUS | 2000 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | TABLET, FILM COATED, EXTENDED RELEASE / ORAL | 119.12 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | GRANULE, FOR SUSPENSION, EXTENDED RELEASE / ORAL | 18790 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | INJECTABLE, LIPOSOMAL / INTRAVENOUS | 7560 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | TABLET / ORAL | 4249 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | SUPPOSITORY / RECTAL | NA | ||
| SUCROSE | SUCROSE | C151H8M554 | ELIXIR / ORAL | 18000 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | POWDER, FOR SOLUTION / ORAL | 38666 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | INJECTION, SUSPENSION, EXTENDED RELEASE / SUBCUTANEOUS | 1 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | DROPS / ORAL | NA | ||
| SUCROSE | SUCROSE | C151H8M554 | POWDER, FOR SUSPENSION / ORAL | 40017 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | INJECTION, POWDER, FOR SUSPENSION / INTRAVENOUS | 900 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | CONCENTRATE / ORAL | 4800 mg |
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| 2914e4e9-2dd3-f40f-e063-6394a90a1b62 | 6ccfc019-f903-48ad-b05e-f560e4a21df9 | 2024-12-12 | Warnings | 2914e4e9-2dd3-f40f-e063-6394a90a1b62 6ccfc019-f903-48ad-b05e-f560e4a21df9 |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.
